H

HUTCHMED (China) Ltd
HKEX:13

Watchlist Manager
HUTCHMED (China) Ltd
HKEX:13
Watchlist
Price: 22.25 HKD 0.45% Market Closed
Market Cap: 19.4B HKD
Have any thoughts about
HUTCHMED (China) Ltd?
Write Note

Gross Margin
HUTCHMED (China) Ltd

41.7%
Current
36%
Average
48.4%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
41.7%
=
Gross Profit
254.5m
/
Revenue
610.8m

Gross Margin Across Competitors

Country HK
Market Cap 19.4B HKD
Gross Margin
42%
Country JP
Market Cap 776 550.9T JPY
Gross Margin
-3%
Country US
Market Cap 756.3B USD
Gross Margin
81%
Country UK
Market Cap 440.4B GBP
Gross Margin
56%
Country DK
Market Cap 2.7T DKK
Gross Margin
85%
Country US
Market Cap 349.7B USD
Gross Margin
69%
Country US
Market Cap 251.6B USD
Gross Margin
77%
Country CH
Market Cap 200.1B CHF
Gross Margin
73%
Country UK
Market Cap 162.1B GBP
Gross Margin
82%
Country CH
Market Cap 171.5B CHF
Gross Margin
75%
Country US
Market Cap 151.4B USD
Gross Margin
71%
No Stocks Found

HUTCHMED (China) Ltd
Glance View

Market Cap
19.4B HKD
Industry
Pharmaceuticals

HUTCHMED (China) Ltd., a hybrid of innovation and tradition, stands at the intersection of global pharmaceutical ambitions and Chinese herbal expertise. Born out of a joint venture between Hutchison Whampoa and Chi-Med, the company has steadily carved out a niche by developing a dual-pronged business model that merges cutting-edge biotechnology with traditional Chinese medicine. This hybrid approach enables HUTCHMED to leverage the best of both worlds by combining the rich pharmacological heritage of China with modern scientific research. Its pipeline includes a range of drugs aimed at treating various cancers and immunological disorders, developed through deep-pocketed collaborations and alliances with multinational corporations. Revenue streams at HUTCHMED primarily flow from drug discoveries and developments that pass through rigorous clinical trials, reaching commercialization both in China and internationally. The company invests significantly in R&D to advance its pipeline, while also generating income through strategic partnerships that involve licensing agreements and joint ventures. This allows HUTCHMED not only to mitigate risks associated with drug development but also to tap into diverse markets by navigating a multifaceted regulatory landscape. By paving the way for western pharmaceutical technologies alongside traditional medicinal insights, HUTCHMED creates a sustainable growth trajectory in an ever-evolving global healthcare market.

Intrinsic Value
21.56 HKD
Overvaluation 3%
Intrinsic Value
Price
H

See Also

Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
41.7%
=
Gross Profit
254.5m
/
Revenue
610.8m
What is the Gross Margin of HUTCHMED (China) Ltd?

Based on HUTCHMED (China) Ltd's most recent financial statements, the company has Gross Margin of 41.7%.